New Antibiotics for Community-Acquired Pneumonia

CAP, community-acquired pneumonia.
^aTwo thousand two hundred and fifty-nine patients with CAP of which 62% were pathogen negative.
^bFour thousand four hundred and thirty-one patients with CAP of which 60% were pathogen negative.
^c Subgroups of the entire respiratory virus cohort.

i.v., intravenous; LFTs, liver function tests; MRSA, methicillin-resistant Staphylococcus aureus; MRSP, macrolide-resistant Streptococcus pneumonia. ↑ indicates mild, ↑↑ indicates moderate, and ↑↑↑ indicates severe elevation or presence. Solithromycin-dosing adjustments may be needed in severe renal insufficiency.

Authors and Disclosures

Marin H. Kollef^a and Kevin D. Betthauser<sup>b

a</sup>Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine and ^bDepartment of Pharmacy Practice, Barnes-Jewish Hospital, St. Louis, Missouri, USA

Correspondence to
Marin H. Kollef, MD, Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, 4523 Clayton Avenue, Campus Box 8052, St. Louis, MO 63110, USA. Tel: +1 314 454 8764; fax: +1 314 454 5571; e-mail: kollefm@wustl.edu

Conflicts of interest
M.H.K. is a consultant to Allergan, Nabriva, and Paratek.

Sidebar

Key Points

• sCAP is an important infection because of the high patient morbidity and mortality, healthcare costs, and antibiotic resistance associated with this condition.

• New antibiotics for the treatment of sCAP provide coverage for current deficits in the available antiinfective armamentarium including susceptibility for methicillin-resistant Staphylococcus aureus and macrolide-resistant Streptococcus pneumoniae.

• Clinicians should develop care pathways at their institutions for the treatment of sCAP in order to optimize patient outcomes while minimizing further emergence of antibiotic resistance.